Peptide drug-drug interactions reference

A patient on warfarin, a thiazide diuretic, and chronic glucocorticoid replacement starts semaglutide for weight management. Three months later, the INR drifts up at a routine check, the morning fasting glucose creeps higher, and the prescribing clinician faces a triage question with several answers behind it. Is the warfarin shift a pharmacokinetic interaction with delayed gastric emptying — or unrelated nutrition change? Is the glucose drift the underlying disease — or a glucocorticoid effect amplified by changing GH-axis tone? Has the thiazide become more or less calcemic against a backdrop of partial weight loss? The same patient on the same medication list could plausibly be experiencing four different interactions simultaneously, none of them at the receptor level the peptide engages.

The frame that "peptides do not have drug interactions because they do not engage CYP450" is the most consequential half-truth in the practitioner-facing peptide literature. The CYP450 observation is largely correct: most therapeutic peptides are catabolized by ubiquitous proteases and peptidases rather than hepatic mitochondrial cytochromes, so the classical small-molecule framework of CYP3A4 inhibitors and inducers altering parent-compound clearance does not apply (Säll et al., Clin Pharmacol Ther 2023, 113:1199–1216). What the half-truth misses is that peptide drugs interact through different surfaces — pharmacodynamic stacking on shared physiological axes, pharmacokinetic effects on co-administered oral medications through delayed gastric emptying, cross-reactivity with monitoring immunoassays, additive effects with concomitant cytotoxic or immunosuppressive therapy, and predictable endocrine-axis cross-talk. The interaction profile of the peptide therapeutic class is not absent. It is different, and the differences are loaded with safety signal.